MBAITechnology · Software - InfrastructureThe 1 Wall Street analysts covering MBody AI Ltd. hold a median 12-month price target of $10 — +232.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores MBody AI Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (82): Smaller than most of the companies we track.
Quality (0): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MBAI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +232.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 Sept 2026 | Northland Capital Markets | Initiates | Outperform | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBAI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 9% of US stocks
Cheaper than 4% of US stocks
Cheaper than 90% of US stocks
Higher than 81% of US stocks
Higher than 83% of US stocks
Higher than 91% of US stocks
Higher than 98% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
MBody AI Ltd. has a market value of $46.0M and an enterprise value of $46.0M.
Trailing P/E: 0.6×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
MBody AI Ltd. employs 85 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own MBody AI Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
MBody AI filed two new patent applications as it continues developing and deploying its Orchestrator enterprise AI workforce platform.
Why it matters — MBAI watchers may note the additional patent applications alongside the company's ongoing work on Orchestrator for enterprise customers.
MBody AI will present its physical AI robotics platform to ThinkEquity and Maxim investors, demonstrating how its Orchestrator runs robots from multiple manufacturers for Fortune 500 hotel and casino operators.
Why it matters — The presentation offers MBAI watchers information about how the company describes its platform and its use with hotel and casino operators.
MBody AI will present its AI robot workforce platform at the Lytham Fall 2026 Conference, with a CEO fireside chat scheduled for September 29 and investor meetings running through September 30. The Nasdaq-listed company operates robot fleets in eleven U.S. states and Canada.
Why it matters — The presentation gives MBAI watchers a formal platform for the CEO to share details on the company's AI robot workforce offering with investors.
MBody AI has completed its name change following a merger and a $10 million offering. The company also introduced its operating platform, enterprise deployments, and updated market identifiers on the Nasdaq.
Why it matters — A MBAI watcher would care because the completed name change and updated market identifiers reflect a formal corporate milestone following the merger and capital raise.
MBody AI Ltd. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference, holding a formal presentation and one-on-one investor meetings from September 14-16, 2026.
Why it matters — The conference gives MBody AI an opportunity to present its business to investors and engage in direct one-on-one meetings with potential stakeholders.
The 1 Wall Street analysts covering MBody AI Ltd. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering MBody AI Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MBody AI Ltd. 10 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, MBody AI Ltd. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (82 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +232.2% from the last close, and Ticker Nerd's factor model ranks MBody AI Ltd. 10 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering MBody AI Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on capsule-based colorectal cancer screening.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform". MBody AI filed two new patent applications as it continues developing and deploying its Orchestrator enterprise AI workforce platform.
Check-Cap Ltd. is a clinical-stage medical diagnostics company focused on capsule-based colorectal cancer screening. The company develops C-Scan, an ingestible imaging capsule system designed to detect precancerous polyps and other abnormalities in the colon using a preparation-free, non-invasive approach. Its technology is intended to support earlier identification of colorectal disease while offering a more patient-friendly alternative to traditional screening methods. Check-Cap Ltd. operates in the health technology and medical devices space, serving the growing demand for accessible diagnostic tools in preventive care. The company is based in Isfiya, Israel, and its current business centers on advancing screening solutions for clinical use and broader adoption in colorectal health management.
CEO Mr. John Fowler · 85 employees · Canada · https://mbody.ai